<DOC>
	<DOCNO>NCT00072072</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth cancer stop blood flow tumor . Erlotinib celecoxib may stop growth tumor cell block enzymes necessary growth . Combining celecoxib erlotinib may kill tumor cell . PURPOSE : This phase I trial study side effect best dose celecoxib give together erlotinib treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Celecoxib Erlotinib Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine biologically active dose celecoxib administer erlotinib patient stage IIIB IV non-small cell lung cancer . - Determine toxicity profile regimen patient . Secondary - Determine clinical activity regimen , term reduction tumor burden , patient . - Correlate biological endpoint cyclooxygenase-2 epidermal growth factor receptor inhibition patient treat regimen . OUTLINE : This nonrandomized , dose-escalation study celecoxib . Patients receive oral erlotinib daily oral celecoxib twice daily day 1-28 . Treatment repeat every 4 week 2 course absence disease progression unacceptable toxicity . Patients stable respond disease may continue treatment beyond 2 course investigator 's discretion . Cohorts 3-6 patient receive escalate dos celecoxib maximum tolerate dose ( MTD ) biologically active dose ( BAD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . The BAD define maximum decrease level PGE_2 DLT occur . Patients follow every 2 month . PROJECTED ACCRUAL : A total 21-27 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB IV Measurable disease Progressive disease least 2 prior standard chemotherapy regimens OR refuse standard chemotherapy No active CNS metastases PATIENT CHARACTERISTICS : Age 21 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal ( ULN ) PT and/or PTT great 1.5 time ULN Renal Creatinine great 2 mg/dL Cardiovascular No New York Heart Association class III IV cardiac disease No myocardial infarction within past year No symptomatic ventricular arrhythmia No symptomatic conduction abnormality Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior gastrointestinal ulceration , bleeding , perforation No hypersensitivity celecoxib , sulfonamide , aspirin , NSAIDs , reagent use study No concurrent disease medical condition would preclude study treatment compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy Endocrine therapy More 4 week since prior corticosteroid No concurrent steroid ( include chronic use ) Concurrent topical steroid allow Radiotherapy More 4 week since prior radiotherapy Surgery Not specify Other More 4 week since prior noncytotoxic investigational agent More 3 day since prior nonsteroidal antiinflammatory drug ( NSAIDs ) No prior cyclooxygenase2 ( COX2 ) inhibitor metastatic NSCLC No prior epidermal growth factor receptor inhibitor metastatic NSCLC No concurrent COX2 inhibitors No concurrent NSAIDs No concurrent fluconazole lithium</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>